title: Glycated albumin modifies platelet adhesion and aggregation responses.
abstract: A diabetic vasculature is detrimental to cardiovascular health through the actions of advanced glycation end products (AGEs) on endothelial cells and platelets. Platelets activated by AGEs agonize endothelial responses promoting cardiovascular disease (CVD) development. While it has been established that AGEs can alter platelet functions, little is known about the specific platelet pathways that AGEs modify. Therefore, we evaluated the effects of AGEs on specific salient platelet pathways related to CVDs and whether the effects that AGEs elicit are dependent on glycation extent. To accomplish our objective, platelets were incubated with reversibly or irreversibly glycated albumin. A time course for adhesion and aggregation agonist receptor expression was assessed. Optical platelet aggregometry was used to confirm the functional activity of platelets after AGE exposure. In general, platelets subjected to glycated albumin had a significantly enhanced adhesion and aggregation potential. Furthermore, we observed an enhancement in dense body secretion and intracellular calcium concentration. This was especially prevalent for platelets exposed to irreversibly glycated albumin. Additionally, functional aggregation correlated well with receptor expression, suggesting that AGE-induced altered receptor sensitivity translated to altered platelet functions. Our findings indicate that under diabetic vascular conditions platelets become more susceptible to activation and aggregation due to an overall enhanced receptor expression, which may act to promote CVD development.
authors.affiliation: a Department of Biomedical Engineering , Stony Brook University , Stony Brook , NY , USA.
authors.forename: Ioana
authors.initials: I
authors.lastname: Soaita
authors.affiliation: a Department of Biomedical Engineering , Stony Brook University , Stony Brook , NY , USA.
authors.forename: Wei
authors.initials: W
authors.lastname: Yin
authors.affiliation: a Department of Biomedical Engineering , Stony Brook University , Stony Brook , NY , USA.
authors.forename: David A
authors.initials: DA
authors.lastname: Rubenstein
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D016718:Arachidonic Acid / Q000494:pharmacology; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D002478:Cells, Cultured; D004837:Epinephrine / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects*; D017127:Glycation End Products, Advanced; D006801:Humans; D010973:Platelet Adhesiveness / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects*; D010979:Platelet Function Tests; D018340:Receptors, Adrenergic, alpha-1 / Q000235:genetics / Q000378:metabolism; D058472:Receptors, Purinergic P2Y1 / Q000235:genetics / Q000378:metabolism; D058925:Receptors, Purinergic P2Y12 / Q000235:genetics / Q000378:metabolism; D044244:Receptors, Thromboxane A2, Prostaglandin H2 / Q000235:genetics / Q000378:metabolism; D012709:Serum Albumin / Q000494:pharmacology*; D000093423:Glycated Serum Albumin
chemical_list: D017127:Glycation End Products, Advanced; C548576:P2RY12 protein, human; D018340:Receptors, Adrenergic, alpha-1; D058472:Receptors, Purinergic P2Y1; D058925:Receptors, Purinergic P2Y12; D044244:Receptors, Thromboxane A2, Prostaglandin H2; D012709:Serum Albumin; D016718:Arachidonic Acid; D000244:Adenosine Diphosphate; D002118:Calcium; D004837:Epinephrine; D000093423:Glycated Serum Albumin
keywords: advanced glycation end products; cardiovascular diseases; diabetes; platelets